Drug-Abuse Nanotechnology: Opportunities and Challenges

ACS Chem Neurosci. 2018 Oct 17;9(10):2288-2298. doi: 10.1021/acschemneuro.8b00127. Epub 2018 May 31.

Abstract

Opioid drug abuse and dependence/addiction are complex disorders regulated by a wide range of interacting networks of genes and pathways that control a variety of phenotypes. Although the field has been extensively progressed since the birth of the National Institute on Drug Abuse in 1974, the fundamental knowledge and involved mechanisms that lead to drug dependence/addiction are poorly understood, and thus, there has been limited success in the prevention of drug addiction and development of therapeutics for definitive treatment and cure of addiction disease. The lack of success in both identification of addiction in at-risk populations and the development of efficient drugs has resulted in a serious social and economic burden from opioid drug abuse with global increasing rate of mortality from drug overdoses. This perspective aims to draw the attention of scientists to the potential role of nanotechnologies, which might pave the way for the development of more practical platforms for either drug development or identification and screening of patients who may be vulnerable to addiction after using opioid drugs.

Keywords: Opioid drug abuse; dependence/addiction; early detection; nanoparticle; nanotechnology; therapeutics.

MeSH terms

  • Blood-Brain Barrier
  • Brain / diagnostic imaging
  • Brain / metabolism*
  • Contrast Media
  • Drug Development
  • Dysbiosis / metabolism
  • Early Diagnosis
  • Gastrointestinal Microbiome
  • Humans
  • Mass Screening
  • Nanotechnology*
  • Opioid-Related Disorders / diagnosis
  • Opioid-Related Disorders / drug therapy*
  • Opioid-Related Disorders / metabolism
  • RNAi Therapeutics
  • Risk Assessment
  • Substance Abuse Detection
  • Substance-Related Disorders / diagnosis
  • Substance-Related Disorders / drug therapy
  • Substance-Related Disorders / metabolism

Substances

  • Contrast Media